Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
24 Julho 2023 - 5:05PM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the
appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief
Business Officer, effective July 10, 2023. Dr. Oliver will oversee
all business development functions and will serve as a member of
the company’s Executive Management Committee, reporting to Steve
Davis, President and Chief Executive Officer of Acadia.
“We are pleased to announce Kevin’s appointment to lead our
business development and partnering activities,” said Steve Davis,
Acadia’s President and Chief Executive Officer. “Our recent
successful launch of DAYBUE™ (trofinetide), the first and only drug
approved for the treatment of Rett syndrome, together with the
continued success of NUPLAZID® (pimavanserin), the first and only
drug approved for the treatment of hallucinations and delusions
associated with Parkinson’s disease psychosis, positions us to
build on our first-to-market expertise as we further expand our
franchises in rare disease and neuropsychiatry.”
Dr. Oliver brings more than three decades of biopharmaceutical
research and development and business development experience to
Acadia. Before joining Acadia, Dr. Oliver served as SVP, Head of
Global Business Development & Licensing and Alliance
Management, as well as Chief Operations Officer, U.S. and Europe at
Simcere Pharmaceutical Group. Prior to Simcere, Dr. Oliver held
various key positions at Merck, where he served for over 20 years
in research and development and business development leadership
roles, and at Alcon as Head of Business Development, Global
External Alliances.
“I am excited to join Acadia at such a pivotal time as we
execute on our company’s strategy to grow our portfolio of central
nervous system assets,” said Dr. Oliver. “The recent success of
DAYBUE, originally partnered for North America in 2018, together
with the recent expansion of this partnership to acquire global
rights, underscores Acadia’s commitment to being the partner of
choice in breakthrough therapies to treat central nervous system
disorders.”
Dr. Oliver obtained his bachelor's degree in Immunology from
King's College London and holds a Ph.D. in Pathology from the
University of Cambridge.
About NUPLAZID® (pimavanserin)
Pimavanserin is a selective serotonin inverse agonist and
antagonist preferentially targeting 5-HT2A receptors. These
receptors are thought to play an important role in neuropsychiatric
disorders. In vitro, pimavanserin demonstrated no appreciable
binding affinity for dopamine (including D2), histamine,
muscarinic, or adrenergic receptors. Pimavanserin was approved for
the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis by the U.S. Food and Drug
Administration in April 2016 under the trade name NUPLAZID. In
addition, Acadia is developing pimavanserin as a potential
treatment for the negative symptoms of schizophrenia.
About DAYBUE™ (trofinetide)
Trofinetide is a synthetic version of a naturally occurring
molecule known as the tripeptide glycine-proline-glutamate (GPE).
The mechanism by which trofinetide exerts therapeutic effects in
patients with Rett syndrome is unknown. In animal studies,
trofinetide has been shown to increase branching of dendrites and
synaptic plasticity signals. 1,2 More information can be found at
DAYBUE.com.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only approved
therapies for hallucinations and delusions associated with
Parkinson’s disease psychosis and for the treatment of Rett
syndrome. Our clinical-stage development efforts are focused on
treating the negative symptoms of schizophrenia, Prader-Willi
syndrome, Alzheimer’s disease psychosis and neuropsychiatric
symptoms in central nervous system disorders. For more information,
visit us at www.acadia.com and follow us on LinkedIn and
Twitter.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug development, approval and commercialization. For a discussion
of these and other factors, please refer to Acadia’s annual report
on Form 10-K for the year ended December 31, 2022, as well as
Acadia’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Acadia undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
References
1 Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of
Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad
Sci USA. 2009;106(6):2029-2034. 2 Acadia Pharmaceuticals Inc., Data
on file. Study Report 2566-026. 2010.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230724050085/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Jessica Tieszen
(858) 261-2950 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024